

[pitch]^{'08}

Alzhyme

Pty Ltd.

“New treatments and early diagnostics for the prevention and cure of Alzheimer’s disease”

Dr Greg Thomas
Chief Executive Officer

Ph: (08) 9480 1184

E-mail: gthomas@alzhyme.com



The Problem



Alzheimer's Disease:


- Significant Market Opportunity

- **20 million people have Alzheimer's disease**
 - **predicted to double by 2025**

- **No disease modifying drugs**
 - **current treatments ease symptoms**

- **Current market US\$2.5 billion**

Our Solution



- **Target the beta-amyloid protein**
- **New class of drug in development for AD**

Improved Diagnosis

- No blood test for Alzheimer's disease
- Early intervention may delay the progression of disease
- Do proteins in the blood hold the key to diagnosis?
- Amyloid imaging agent for PET


“New treatments and early stage diagnostics for the prevention and cure of Alzheimer's disease”

Our Business Model

- Add value to technologies in staged processes
- Building partnerships



CSIRO



Bio-Layer

Materials Science for Diagnostics
and Biomedical Applications



Our Business Model

- **Offer balanced portfolio of pre-clinical and early clinical compounds**
- **Not single product company**
 - Build portfolio including diagnostics
 - Look to in-license late stage compounds
- **Build products to exit – (IPO / trade sale)**

Our Assets

Why Invest in Alzhyme?

- People, Technology and Market

- **High quality science lead by Prof Ralph Martins**
- **World class Scientific Advisory Board**
- **Strong academic and clinical research links**



Our Assets

Why Invest in Alzhyme?

- People, Technology and Market

- **Board with direct experience in building value**



- **Fully assigned Intellectual Property**



The Ask



- **Seed/Series A – Use of proceeds**
 - Complete lead optimization program
 - Commence GLP toxicology testing
 - Business Development
- **>20x return at exit for Seed/Series A investors in 4-5 years**